Document:

Exhibit 10.2

 

Plasma Exosome Concentration in Cancer Patients
Undergoing Treatment

 

Objectives of the
Study:

 

This
is a pilot study of a putative biomarker, circulating exosomes, which are increased in patients with cancer and hypothesized to
play a role in tumor-associated immune suppression. We will address the following Specific Aims:

 

		1)	Characterize the baseline concentration of circulation
exosomes in patients with various tumor types (in and around the time of diagnosis) and the kinetics of longitudinal changes in
the circulating exosome concentration associated with primary therapy (surgery, radiation therapy, chemotherapy, and/or neoadjuvant
chemotherapy).

		2)	In patients with metastatic tumor burden, examine baseline
and longitudinal changes associated with chemotherapy treatment.

		3)	In patients with metastatic tumor burden evaluate associations
between changes in circulating exosome concentrations and response to chemotherapy.

 

RESEARCH DESIGN
AND METHODS

Overview of Study
Design

This
proposed clinical study will provide critical initial data to direct future clinical investigations of a novel treatment approach
using extracorporeal hemofiltration for the removal of tumor-derived exosomes. Exosomes are small, 30-120 nm, membrane bound vesicles
shed from all cells, but at higher levels from tumor cells [1], providing a logical candidate for the association between tumor
burden and tumor-associated immune suppression. First described > 30 years ago, exosomes were originally thought to be cellular
“garbage bags,” found in the peripheral blood, containing proteins (including various receptors and signaling molecules)
and nucleic acids, (genomic, mRNA, and microRNAs) [1, 2]. Exosomes are now recognized to have many biological functions including
expressing tumor associated antigens [3-7], to tumor-associated immune suppression [8-19], and have been hypothesized to directly
contribute to the metastatic process and treatment resistance, but with mechanisms less well characterized [8, 12, 20-23]. It
has been observed that circulating exosome concentration is increased in patients with metastatic melanoma, ovarian epithelial,
prostate and colorectal neoplasms [24-29] and as such is hypothesized to vary with tumor burden.

 

Exosome ELLSA:

Previous studies have established that tumor-
secreted exosomes display high mannose glycoprotein signatures on their surfaces [30], thus sharing this feature in common with
enveloped viruses. To this end, Aethlon has examined exosomes from various tumor sources and tested their binding to GNA affinity
matrices, in vitro, in studies with Dr. Douglas Taylor. In a variation of a traditional ELISA, GNA was used as a substrate
for coating plates to measure exosome binding, enzyme linked lectin sorbent assay (ELLSA). Ovarian cancer exosomes that were purified
by a conventional ultracentrifugation method bound to GNA and were detectable against a mannan standard curve, Figure 1.

 

 

FIGURE 1. Exosome ELLSA. Binding of purified
exosomes from an ovarian cancer patient (obtained by ultracentrifugation) to GNA coated plates (1 μg/mL) in a modified
ELISA assay using serial dilutions of mannan and HRP labeled GNA as a detection agent to generate a standard curve.

 

 

    	1

    	 

    

 

Aethlon’s initial studies were
conducted by Dr. Douglas Taylor using exosomes from ovarian cancer patients. Exosomes were purified from ascites fluid of two
ovarian cancer patients using an established ultracentrifugation method [31, 32] or using the Hemopurifier®. The
Hemopurifier® provides the capacity to elute adsorbed exosomes for subsequent evaluation. Analysis of the
tumor-associated exosome marker, EpCAM, revealed that the presence of EpCAM in the material eluted from the
Hemopurifier® as well as in the control exosome preparation, Figure 2 Panel A.

 

 

 

FIGURE
2. Panel A: Western blot for EpCam in conventionally purified exosomes and exosomes eluted from the Hemopurifier from ascites
of 2 cancer patients. Panel B: Effect of co-culture of eluted exosomes at increasing concentrations with Jurkat T cells followed
by western blotting of cell lysates for CD3 zeta chain and phospho JAK3. C=control (no exosomes).

 

Subjects and Recruitment:

Subject Recruitment/Informed
Consent: Recruitment of participants in the study will be through the use of internal and outside referrals to the University
of California, Irvine (UCI) Medical Center (UCIMC). Review and approval of this human protocol will be conducted by the UCI Institutional
Review Board (IRB) Human Subjects Review Committee. Subjects must be able to understand and sign an informed consent form, which
must comply with U.S. regulations (U.S. 21 CFR 50) and ICH guidelines to be eligible for this trial. All study materials, including
consent forms will be provided in the patient’s primary language. In addition, each subject will be given a copy of the
consent form, the Experimental Subjects’ Bill of Rights, and HIPAA Release form, all of which will be explained to the subject.

 

Accrual Capacity:
The NCI designated Chao Family Comprehensive Cancer Center (CFCCC) at UCI has an active clinical cancer care and research
program. UCI Medical Center has a large referral base and sufficient numbers of patients will be available for enrollment onto
the protocol described herein. Data from the cancer registry documents that over the past three years, we have seen a steady rise
from our baseline of approximately 1700 individual new “analytic” patients: 2010 = 1697, 2011 = 2000, 2012 = 2164,
2013 = 2189 (with 257 of these being new cases with metastatic disease) and are on track for a further increase in 2014. We have
an outstanding record of accrual to clinical trials with over 24% of patients being accrued to clinical studies in each of these
three years; the national average at NCI designated comprehensive cancer centers is 15% and nation wide is only 5%. Even given
a conservative 30% accrual rate of screened and eligible patients and not accounting from recruitment from the larger surrounding
non-UCI affiliated oncology care community, we have adequate capacity to successfully complete accrual to this study.

 

 

 

    	2

    	 

    

 

 

Study Population
Demographics: Those who satisfy the inclusion/exclusion criteria and will be enrolled in the study. Patient enrollment
will include all ethnic groups and both genders as available. The current demographics of the patient population seen at CFCCC
and the University of California at Irvine Medical Center are as follows: 42% male; 59% female; 45%Caucasian; 5% Black; 20% Asian;
30% Hispanic.

 

Study Endpoints

A. Baseline circulating exosome concentration

B. Longitudinal changes in circulating exosome concentrations
associated with tumor treatment.

C.
Association of longitudinal changes in circulating exosome concentrations with response to treatment.

 

Evaluation of clinical outcome per se,
(i.e., progression free or overall survival) is beyond the scope of this pilot study, we will explore potential associations with
clinical outcomes and the putative biomarker, circulating exosome concentration which will provide additional pilot data to direct
future studies.

 

Study Population - Patient Inclusion
and Exclusion Criteria

Patients with a diagnosis of cancer are
potential subjects for this study.

In order to be eligible for this study, patients must meet all of the following criteria:

1. Patients must have a histologically proven diagnosis
of cancer.

2. Have measurable tumor burden.

3. Expected survival must be greater than six (6) months.

4.
A Karnofsky Performance Status (KPS) must be 70 or greater, equivalent to ECOG 0 to ≈2 (Appendix A).

5. Patients must be >21 years of age.

6. Patients
must be able to understand and sign an informed consent form, which must comply with U.S. regulations (U.S. 21 CFR 50) and ICH
guidelines.

 

Patients with any one of
the following conditions must be excluded from this trial:

1. History of repeated central line associated thrombosis
or bleeding diathesis.

2. Chronic anti-coagulation therapy.

3. More than one malignant diagnosis, except for the
basal cell epithelioma of the skin.

4. Persistent fever greater than 38 C.

5. Calculated CrCl less than 60 ml/min.

6.
Required use of chronic corticosteroids or immune suppression for any reason including an organ allograft or HIV infection

7.
Patients with any acute or chronic illness including cardiovascular disease or history of myocardial infarction, autoimmune state,
or any psychiatric illness that in the opinion of the Investigators would compromise treatment.

 

Study Design/Sample
Size:

As this is a pilot,
hypothesis generating early phase non-randomized, clinical study, designed to provide initial characterization of a tumor biomarker,
and is not a hypothesis testing Phase II or III study, standard calculations of “power” or “sample size”
are not appropriate or applicable for this study. It is not known if there are significant differences in circulating exosome
concentrations by tumor type, treatment type, or kinetics of treatment response. Thus, the final target study cohort size will
be dependent upon early observations in a range of subjects from various tumor types. We will employ cohort expansion modifications
as indicated. We initially plan on enrolling 5 patients with defined tumor types, see table next page, for a total initial study
population of 45 subjects.

 

 

    	3

    	 

    

 

If analysis of
the initial 5 subjects with a given tumor type suggests impact of histologic subtype (e.g. for breast cancer – hormone
receptor positive, HER2/neu positive, triple negative, lobular vs. ductal), treatment type or kinetics of treatment response;
expansion cohorts consisting of 5 subjects will be added, via modification of the IRB approved protocol, as needed to
characterize the impact of these factors on circulating exosome concentrations.

	Tumor Type	Study Cohort	
        Approximate number of cases at UCIMC on

        treatment with tumor present - 2013

	Breast adenocarcinoma	5	30
	Colorectal	5	21
	Gastric & Gastroesophageal	5	30
	Pancreatic	5	60
	Cholangiocarcinoma	5	9
	Lung (NSCLC)	5	44
	Head & Neck (SCC)	5	42
	Melanoma	5	22
	Ovarian adenocarcinoma	5	23

 

Research Methodology/Study
Procedures

 

Enrolled subjects will
have standard phlebotomy performed with collection of blood into 4 ml vacutainer tubes containing K2EDTA anticoagulant. These
tubes will be transported to Dr. Nelson’s laboratory at 4 C (in the presence of a cool pack) for centrifugation at 300 g
(≈ 1200 RPM for tabletopcentrifuge - Beckman GH-3.8). Plasma will be removed from the vacutainer tube and distributed as
1 ml aliquots into 1.5 ml eppendorf snap top tubes labeled with the subjects 4 digit study ID number (e.g. 1001, cohort 1, subject
#1). These tubes will be placed at -80 C until shipment on dry ice to Princeton NJ, for assay of exosome concentration.

 

Subjects will have phlebotomy
performed immediately before the administration of treatment, primary treatment or treatment for advanced disease. This blood
sample will be collected prior to the administration of any pre-medications for subsequent treatment, (surgery, chemotherapy,
chemoradiation, or radiation alone, the latter will be rare). Each sample will be labeled to identify the patient as with any
other biospecimen collected for clinical evaluation. Ideally, the first sample will be collected before any treatment has been
initiated, however there is no absolute requirement that the patients have not received prior treatment if they have advanced
disease. For those patients continuing treatment but with measurable, advanced disease, progression free survival and time to
treatment failure will have less meaning and we hypothesize, will be less likely to demonstrate associations with circulating
exosome concentrations. Never the less, the first collection will be considered the patient’s baseline value. For multiple
day regimens, patients will have 4 ml of blood collected on the first and last day of the chemotherapy regimen. Additional 4 ml
samples will be collected no more frequent than weekly during the first four weeks of enrollment on this protocol. Thus, regardless
of whether treatment is primary (for a new diagnosis and therefore potentially primary surgical treatment), is neoadjuvant, or
is secondary for advanced disease the subjects will get a minimum of 4 x 4 ml phlebotomy samples collected in the first month.
Thereafter, phlebotomy will be performed with each cycle of chemotherapy (neoadjuvant or secondary) or with each post primary
treatment follow-up visit for no more than 6 months from the baseline collection.

 

 

 

    	4

    	 

    

 

 

Endpoint Data and Evaluations:

Circulating Exosome
Concentrations:

Samples of plasma shipped
frozen to Princeton NJ, will be analyzed in replicate via the ELLSA assay described above, quantifying the concentration of circulating
exocomes in each sample. Raw and mean data will be provided for data analyses. Grubbs test will be used to identify outliers from
triplicate or larger replicate determinations of exosome concentration from each sample.

 

Other Data to be
Collected:

Treatment and
Response: Patients may be receiving so called “targeted therapies”, standard cytotoxic chemotherapy, combined
chemoradiation, and/or symptomatic/palliative support without cytotoxic therapies. Select agents can induce different types of
tumor cell death and may have different effects on the release of tumor-associated exosomes. It is conceivable that an immediate
and profound cytotoxic effect may lead to a transient “bolus” release of tumor-associated exosomes. Thus, treatment
administered will be collected to investigate the impact of particular agents or combinations thereof, on the longitudinal changes
in circulating exosome concentration. Additionally, we will collect tumor response data from the clinician’s notes to assess
the association between changes in tumor burden and the longitudinal changes in circulating exosome concentrations.

 

Progression Free
Survival and Time to Relapse:  All patients will be followed from the time of enrollment for PFS and TTR for a maximum
of five years. These clinical parameters will be used to investigate potential associations with longitudinal changes in the circulating
exosome concentration.

 

Sociodemographic
Characteristics: Race and ethnicity will be recorded for all participants in order to ascertain whether these impact circulating
exosome concentration. This will inform the design of future studies. In addition, the use of prescription and nonprescription
medications will be recorded as these may also confound the circulating exosome concentration.

 

Cancer & Medical
History: Diagnosis, prior treatment, comorbidities, as well as histology classification will be recorded. Social
history including education level, activity level, will also be recorded to investigate potential confounding co-variables.

 

Statistical Considerations
& Data Analysis

Descriptive statistics
will be computed to summarize demographic and background variables, efficacy variables and toxicity variables. Comparisons of
baseline characteristics will be performed using univariate analysis of variance for continuous variables and Chi-square analyses
for categoric variables. Changes over time in circulating exosome concentrations and associations with other categoric variables
will be evaluated by multivariate analysis of variance methods for repeated measures. Because this is an early phase study, the
sample size is not based on the power necessary to test a hypotheses for a given or expected effect size.

 

Risk

The risk to the subjects
is limited to the risk of phlebotomy and the risk of breach of HIPAA security Phlebotomy Risk: Collection of blood during
the phlebotomy visit may cause pain, brief dizziness, possible fainting, slight bleeding, swelling or bruising at the collection
site, and a very remote chance of infection.To minimize this risk certified and experienced phlebotomists or RNs will collect
the specimens.

 

 

    	5

    	 

    

 

HIPAA Risk: We
recognize that there is a risk for confidential information to be exposed. Biomarkers are stored in Dr. Nelson’s laboratory.
Clinical data is maintained within the EMR and if transferred to any desktop computer, that computer will be maintained in a locked
office, encrypted and password protected in accordance with University of California policies. Access to the computers and files
is restricted by a high security system through password. Within our secure network, data will only be accessible to the study
personnel who have signed confidentiality agreements, taken online IRB tutorials for the protection of human subjects and taken
the Health Insurance Portability and Accountability Act online tutorial. Computers are located in offices where office doors are
closed and locked after working hours and during weekends. All office doors are locked after working hours and during weekends.
To additionally protect the confidentiality of participants, our central informatics system includes the following features: 1)
use of encryption software to secure data transport; 2) a firewall system that protects the informatics network from intrusion
or unauthorized access; 3) access to the central informatics system requires a valid password; 4) confidential data are stored
in a separate secure database table and linked to data in other tables by a number only with no personal identifiers; 5) extract
files and reports will not contain any confidential information.

 

Potential Benefits
of the Proposed Research to Subjects and Others:

There will be no benefits for participants in the study.

 

 

    	6

    	 

    

 

References:

		1.	Thery, C., Exosomes: secreted vesicles and intercellular
communications. F1000 Biol Rep, 2011. 3: p. 15.

		2.	Valenti, R., et al., Human tumor-released microvesicles
promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Cancer Res,2 006. 66(18): p. 9290-8.

		3.	Schartz, N.E., et al., From the antigen-presenting
cell to the antigen-presenting vesicle: the exosomes. Curr Opin Mol Ther, 2002. 4(4): p. 372-81.

		4.	Wolfers, J., et al., Tumor-derived exosomes are a
source of shared tumor rejection antigens for CTL cross-priming. Nat Med, 2001. 7(3): p. 297-303.

		5.	Mignot, G., et al., Prospects for exosomes in immunotherapy
of cancer. J Cell Mol Med, 2006. 10(2): p. 376-88.

		6.	Delcayre, A. and J.B. Le Pecq, Exosomes as novel
therapeutic nanodevices. Curr Opin Mol Ther, 2006. 8(1): p. 31-8.

		7.	Hao, S., T. Moyana, and J. Xiang, Review: cancer
immunotherapy by exosome-based vaccines. Cancer Biother Radiopharm, 2007. 22(5): p. 692-703.

		8.	Filipazzi, P., et al., Recent advances on the role
of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol, 2012. 22(4): p. 342-9.

		9.	Whiteside, T.L., Immune modulation of T-cell and
NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans, 2013. 41(1): p. 245-51.

		10.	Marton, A., et al., Melanoma cell-derived exosomes
alter macrophage and dendritic cell functions in vitro. Immunol Lett, 2012. 148(1): p. 34-8.

		11.	Peng, P., Y. Yan, and S. Keng, Exosomes in the ascites
of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep, 2011. 25(3): p. 749-62.

		12.	Azmi, A.S., B. Bao, and F.H. Sarkar, Exosomes in
cancer development, metastasis, and drug resistance: a comprehensive review. Cancer Metastasis Rev, 2013.

		13.	Chalmin, F., et al., Membrane-associated Hsp72 from
tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells.
J Clin Invest, 2010. 120(2): p. 457-71.

		14.	Xiang, X., et al., TLR2-mediated expansion of MDSCs
is dependent on the source of tumor exosomes. Am J Pathol, 2010. 177(4): p. 1606-10.

		15.	Liu, Y., et al., Contribution of MyD88 to the tumor
exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol, 2010. 176(5): p. 2490-9.

		16.	Xiang, X., et al., Induction of myeloid-derived suppressor
cells by tumor exosomes. Int J Cancer, 2009. 124(11): p. 2621-33.

		17.	Yu, S., et al., Tumor exosomes inhibit differentiation
of bone marrow dendritic cells. J Immunol, 2007. 178(11): p. 6867-75.

		18.	Clayton, A., et al., Human tumor-derived exosomes
selectively impair lymphocyte responses to interleukin-2. Cancer Res, 2007. 67(15): p. 7458-66.

		19.	Peche, H., et al., Induction of tolerance by exosomes
and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant, 2006. 6(7): p. 1541-50.

		20.	Rana, S., K. Malinowska, and M. Zoller, Exosomal
tumor microRNA modulates premetastatic organ cells. Neoplasia, 2013. 15(3): p. 281-95.

		21.	Hood, J.L., R.S. San, and S.A. Wickline, Exosomes
released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res, 2011. 71(11): p. 3792-801.

		22.	Aung, T., et al., Exosomal evasion of humoral immunotherapy
in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A, 2011. 108(37): p.15336-41.

		23.	Pilzer, D., et al., Emission of membrane vesicles:
roles in complement resistance, immunity and cancer. Springer Semin Immunopathol, 2005. 27(3): p. 375-87.

		24.	Jimenez, C.R., et al., Proteomics of colorectal cancer:
overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers.
J Proteomics, 2010. 73(10): p. 1873-95.

		25.	Khan, S., et al., Plasma-derived exosomal survivin,
a plausible biomarker for early detection of prostate cancer. PLoS One, 2012. 7(10): p. e46737.

		26.	Kucharzewska, P., et al., Exosomes reflect the hypoxic
status of glioma cells and mediate hypoxia- dependent activation of vascular cells during tumor development. Proc Natl Acad
Sci U S A, 2013. 110(18): p. 7312-7.

		27.	Liang, B., et al., Characterization and proteomic
analysis of ovarian cancer-derived exosomes. J Proteomics, 2013. 80C: p. 171-182.

		28.	Logozzi, M., et al., High levels of exosomes expressing
CD63 and caveolin-1 in plasma of melanoma patients. PLoS One, 2009. 4(4): p. e5219.

		29.	Silva, J., et al., Analysis of exosome release and
its prognostic value in human colorectal cancer. Genes Chromosomes Cancer, 2012. 51(4): p. 409-18.

		30.	Batista, B.S., et al., Identification of a conserved
glycan signature for microvesicles. J Proteome Res, 2011. 10(10): p. 4624-33.

		31.	Momen-Heravi, F., et al., Current methods for the
isolation of extracellular vesicles. Biol Chem, 2013. 394(10): p. 1253-62.

		32.	Thery, C., et al., Isolation and characterization
of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol, 2006. Chapter 3: p. Unit 3 22.

 

 

 

    	7Exhibit 10.3

 

Protocol No.: UCI 14-25 Plasma Exosome Concentration in Cancer
Patients Undergoing Treatment

 

Protocol Target Accrual: 45                                                                              PI: Edward Nelson, MD

Short Title:
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment

 

Startup Charges

	Event	Negotiated Charge
	 	 
	Protocol Set-Up & Administration Fees (Feasibility, Budget, Medicare Cost Coverage, IRB
    Application/Doc Prep, IRB Institutional Review Fee, Annual CRC Administrative Fees, and Study Supplies)	
        15,105.00    

 

	Subtotal:	 	 	15,105.00	 
	Overhead Charges @ 0.0%:	 	 	0.00	 
	Indirect Costs @ 26.0%:	 	 	3,927.30	 
	Total Startup Charges:	 	 	19,032.30	 

 

Per Subject Visit Charges (Items include 26.0% indirect charges)

 

	# occurances	Event	# of Subjects	Visit Reimbursement
	1	Phlebotomy	45	84.00
	1	Cancer Center Data Management	45	1,497.00
	1	Study Oversight, Coordination, and Biostatistics	45	1,778.00
	 	Total Subject Charges (Maximum)	 	3,359.00

 

	Direct Cost Subtotal for (1) Subjects:	 	 	2,665.87	 
	Indirect Costs @ 26.0%:	 	 	693.13	 
	Total Per Subject Charges for (1) Subjects	 	 	3,359.00	 
	Total Per Subject Charges for (45) Subjects	 	 	151,155.00	 

 

Protocol Related Variable Passthrough Charges (Items include
26.0% indirect charges)

 

	Event	 	 	Negotiated Charge	 
	Protocol Annual Renewal Prep Fee (Payment triggered at IRB renewal. Includes study project management outside visit activities for sponsor site visits, IRB renewal prep, bill reconciliation, OnCore managment, SAE reporting, IRB modifications, close out and storage, etc.)	 	 	7,000.00	 
	IRB Committee Renewal Review Fee	 	 	1,039.50	 
	Consent Translation (Pass through cost, based on language and length of document)	 	 	TBD	 
	Other Tests/Procedures not included above	 	 	TBD

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00243-of-00352.parquet"}]]